CAR Macrophages Targeting c-MET in Advanced Pancreatic Cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new type of cell therapy using your own immune cells (macrophages) that have been engineered to fight pancreatic cancer. The study is for patients with advanced pancreatic cancer that has spread or cannot be surgically removed, and whose cancer has not responded well to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced pancreatic cancer (locally unresectable or spread to the abdomen/pelvis) confirmed by biopsy or imaging
- Your cancer has already been treated with at least one prior therapy, or you could not tolerate that therapy
- Your cancer cells must show medium-to-high expression of a protein called c-MET (a specific marker the engineered cells target)
- You have adequate organ function (normal blood counts, kidney, liver, and heart function) as shown by recent lab tests
- You are age 18–75 and in good enough health to tolerate treatment (ECOG performance status 0–1)
- You do not have serious infections (HIV, hepatitis B or C, active tuberculosis), autoimmune disease, severe heart problems, or recent gastrointestinal bleeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T) that targets two markers on pancreatic cancer cells. It's for people with advanced pancreatic cancer who have already tried standard chemotherapy.
This trial tests a new type of immunotherapy called CAR-NK cells (CL-NK-001) for patients with advanced pancreatic cancer that has a specific marker (eGR1). The goal is to see if these specially grown natural killer cells can attack the cancer after standard treatments have stopped working.
This trial tests a new treatment using immune cells (CAR-NK cells) to fight pancreatic cancer that has spread or come back. It may be an option if standard treatments have stopped working, were not tolerated, or were refused.
This trial tests a new immune cell therapy (EGFRBi armed PBMC) for people with advanced pancreatic cancer that can't be removed by surgery. It aims to see if this treatment can help control the cancer after you've already tried at least one type of chemotherapy and your disease is stable or better.
This Phase 2 trial studies a combination of immunotherapy, a blood-vessel/immune signal blocker, and chemotherapy for people with metastatic pancreatic adenocarcinoma. It may help shrink tumors and improve control of the disease.
This trial tests a new treatment using your own immune cells, called macrophages, that are specially designed to attack cancer cells based on certain markers (like HER2). It is for people with advanced solid tumors who have already tried other treatments and need a new option.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.